11:01 AM EDT, 09/25/2025 (MT Newswires) -- Apogee Therapeutics ( APGE ) shares have room to appreciate, especially with additional clinical data on the horizon, RBC Capital Markets said in a note Thursday.

Analysts, including Brian Abrahams, said that they are optimistic about the company and its potential to deliver biologic drugs that are meaningfully different from current treatments. Based on preclinical studies, early clinical trials, and more recent phase 2 data in atopic dermatitis, or AD, they believe Apogee's lead antibody candidate, referred to as '777, and its combination therapies, show clear advantages.

The drug targets are already well-established, which lowers the overall development risk. In addition, key opinion leaders have expressed positive views on the convenience of Apogee's dosing schedule, which they see as a major point of differentiation in the clinic, the analysts said.

They added that, combined with "large" revenue potential across multiple immunology and inflammation diseases, most of which the market is currently underestimating, they see share appreciation potential with upcoming clinical data.

"We see a highly promising profile for lead monoclonal antibody '777, with likelihood of additional de-risking over the next 12 months," the analysts said.

RBC initiated Apogee Therapeutics ( APGE ) at outperform, speculative risk with a $60 price target.

Price: 38.06, Change: -0.36, Percent Change: -0.94